Enovis (NYSE:ENOV) Director Angela Lalor Acquires 870 Shares of Company Stock

Enovis Corporation (NYSE:ENOV) Director Angela Lalor bought 870 shares of the company’s stock in a transaction dated Wednesday, November 11th. The stock was bought at an average cost of $28.86 per share, with a total value of $25,108.20. Following the transaction, the director directly owned 33,243 shares in the company, valued at approximately $959,392.98. The trade was a 2.69% increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Enovis Stock Performance

Shares of Enovis stock opened at $27.63 on Friday. The firm has a market cap of $1.59 billion, a PE ratio of -3.00 and a beta of 1.31. The firm’s 50-day simple moving average is $20.36 and its 200-day simple moving average is $23.19. The company has a debt-to-equity ratio of 0.82, a quick ratio of 1.08 and a current ratio of 2.15. Enovis Corporation has a 1 year low of $16.70 and a 1 year high of $31.81.

Enovis (NYSE:ENOV) last issued its quarterly earnings results on Thursday, November 5th. The company reported $0.88 EPS for the quarter, topping the consensus estimate of $0.77 by $0.11. The business had revenue of $558.73 million for the quarter, compared to analysts’ expectations of $557.12 million. Enovis had a negative net margin of 22.86% and a positive return on equity of 13.23%. The company’s quarterly revenue was up 1.8% compared to the same quarter last year. During the same quarter last year, the company posted $0.75 earnings per share. Equities analysts forecast that Enovis Corporation will post 3.15 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts have recently commented on the company. Wells Fargo & Company lifted their target price on Enovis from $33.00 to $37.00 and gave the stock an “overweight” rating in a research report on Friday, November 6th. Citizens Jmp dropped their price target on Enovis from $55.00 to $47.00 and set a “market outperform” rating on the stock in a research report on Wednesday, September 2nd. UBS Group reissued a “buy” rating and set a $44.00 price target on shares of Enovis in a research report on Monday, October 5th. Wall Street Zen upgraded Enovis from a “hold” rating to a “buy” rating in a research note on Saturday, October 31st. Finally, Needham & Company LLC lifted their price objective on shares of Enovis from $34.00 to $38.00 and gave the stock a “buy” rating in a report on Thursday, November 5th. Ten investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $38.62.

Institutional Investors Weigh In On Enovis

Several institutional investors and hedge funds have recently bought and sold shares of the business. Paradigm Capital Management Inc. NY boosted its stake in Enovis by 70.2% in the first quarter. Paradigm Capital Management Inc. NY now owns 1,776,715 shares of the company’s stock valued at $40,420,000 after acquiring an additional 732,917 shares during the period. Private Management Group Inc. raised its position in shares of Enovis by 31.3% during the 3rd quarter. Private Management Group Inc. now owns 1,792,429 shares of the company’s stock worth $32,748,000 after purchasing an additional 427,347 shares during the period. Allspring Global Investments Holdings LLC raised its position in shares of Enovis by 38.0% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 1,045,360 shares of the company’s stock worth $24,430,000 after purchasing an additional 287,687 shares during the period. Front Street Capital Management Inc. raised its position in shares of Enovis by 106.1% during the 1st quarter. Front Street Capital Management Inc. now owns 746,056 shares of the company’s stock worth $16,973,000 after purchasing an additional 384,124 shares during the period. Finally, Quantinno Capital Management LP lifted its holdings in shares of Enovis by 130.8% in the 1st quarter. Quantinno Capital Management LP now owns 604,500 shares of the company’s stock worth $13,752,000 after purchasing an additional 342,556 shares during the last quarter. Institutional investors and hedge funds own 98.45% of the company’s stock.

Top Enovis Stories

These are some of the ENOV stories that stood out recently:

• Positive Sentiment: Directors Angela S. Lalor and Sharon L. Wienbar reported purchases on November 10 and 11, totaling 3,531 shares worth about $100,000. The buying may bolster investor confidence, although the transactions are relatively modest and do not guarantee future performance. Lalor SEC filing Wienbar SEC filing
• Neutral Sentiment: Enovis said management will present at the Jefferies Global Healthcare Conference in London on November 17. The announcement provides an opportunity for investors to hear from management but disclosed no new financial guidance or business developments. Conference announcement

Enovis Company Profile

Enovis is a medical technology company that develops products and solutions for orthopedic care, surgery, recovery and rehabilitation. Its offerings include joint replacement implants, foot and ankle products, surgical instruments, orthopedic braces and supports, and rehabilitation equipment. The company serves healthcare providers and patients in markets around the world. Its products are designed to support treatment across different stages of musculoskeletal care, from surgical intervention to recovery and mobility.